VATS versus Open Lobectomy following Induction Therapy for Stage III NSCLC: A Propensity Score-Matched Analysis
Open Access
Abstract
Objectives: This study aims to evaluate the perioperative and oncologic outcomes of thoracoscopic lobectomy for advanced stage III NSCLC. Methods: We retrospectively reviewed 205 consecutive patients who underwent VATS or open lobectomy for clinical stage III lung cancer between January 2013 and December 2020. The perioperative and oncologic outcomes of the two approaches were compared. Long-term survival was assessed using the Kaplan–Meier estimator. Propensity score-matched (PSM) comparisons were used to obtain a well-balanced cohort of patients undergoing VATS and open lobectomy. Results: VATS lobectomy was performed in 77 (37.6%) patients and open lobectomy in 128 (62.4%) patients. Twelve patients (15.6%) converted from VATS to the open approach. PSM resulted in 64 cases in each group, which were well matched according to twelve potential prognostic factors, including tumor size, histology, and pTNM stage. Between the VATS and the open group, there were no significant differences in unmatched and matched analyses, respectively, of the overall postoperative complications (p = 0.138 vs. p = 0.109), chest tube duration (p = 0.311 vs. p = 0.106), or 30-day mortality (p = 1 vs. p = 1). However, VATS was associated with shorter hospital stays (p < 0.0001). The five-year overall survival (OS) and five-year Recurrence-free survival (RFS) were comparable between the VATS and the open groups. There was no significant difference in the recurrence pattern between the two groups in both the unmatched and matched analyses. Conclusion: For the advanced stage III NSCLC, VATS lobectomy achieved equivalent postoperative and oncologic outcomes when compared with open lobectomy without increasing the risk of procedure-related locoregional recurrence.Keywords
This publication has 37 references indexed in Scilit:
- Comparison of clinical outcomes for patients with clinical N0 and pathologic N2 non‐small cell lung cancer after thoracoscopic lobectomy and open lobectomy: A retrospective analysis of 76 patientsJournal of Surgical Oncology, 2012
- Safety of Thoracoscopic Lobectomy in Locally Advanced Lung CancerAnnals of Surgical Oncology, 2011
- Efficacy of Mediastinal Lymph Node Dissection During Lobectomy for Lung Cancer by Thoracoscopy and ThoracotomyThe Annals of Thoracic Surgery, 2011
- Patterns of recurrence and incidence of second primary tumors after lobectomy by means of video-assisted thoracoscopic surgery (VATS) versus thoracotomy for lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2011
- Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2010
- Phase II Trial of a Trimodality Regimen for Stage III Non–Small-Cell Lung Cancer Using Chemotherapy As Induction Treatment With Concurrent Hyperfractionated Chemoradiation With Carboplatin and Paclitaxel Followed by Subsequent Resection: A Single-Center StudyJournal of Clinical Oncology, 2010
- Is video-assisted thoracoscopic surgery a feasible approach for clinical N0 and postoperatively pathological N2 non-small cell lung cancer?☆European Journal of Cardio-Thoracic Surgery, 2008
- Thoracoscopic Lobectomy Facilitates the Delivery of Chemotherapy after Resection for Lung CancerThe Annals of Thoracic Surgery, 2007
- Video-Assisted Thoracoscopic Surgery Lobectomy for c-T1N0M0 Primary Lung Cancer: Its Impact on Locoregional ControlThe Annals of Thoracic Surgery, 2006
- Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality ProtocolJournal of Clinical Oncology, 2005